D- erythro- 2- N- (160- (1''- pyridinium)hexadecanoyl)sphingosine bromide

09/05/2013 - "In contrast, the same LCL30 treatment combined with Pc4-PDT had no significant effect on tumor response. "
09/05/2013 - "These results with LCL30 and LCL85, and our previous findings for LCL29 (another SL analogue), assert the potential of SLs for use as adjuvants to augment the efficacy of PDT-mediated tumor destruction. "
09/05/2013 - "Cationic ceramides and analogues, LCL30 and LCL85, as adjuvants to photodynamic therapy of tumors."
09/05/2013 - "Photofrin-PDT, used at a dose that attained good initial response but no tumor cures, produced 50% cures when combined with a single LCL30 treatment. "
09/05/2013 - "LCL85, the cationic B13 ceramide analogue and SL-modulating agent, also increased cure rates of Photofrin-PDT treated tumors, but the therapeutic benefit was less pronounced than with LCL30. "

01/15/2008 - "We found that LCL-30 accumulated in mitochondria in the murine colorectal cancer cell line CT-26 and reduced cellular ATP content, leading to dose- and time-dependent cytotoxicity. "
01/15/2008 - "Mitochondrially targeted ceramide LCL-30 inhibits colorectal cancer in mice."

01/01/2011 - "Using SCCVII mouse squamous carcinoma cells, and the silicone phthalocyanine Pc 4 for PDT, we showed that combining PDT with LCL30 (PDT/LCL30) was more effective than individual treatments in raising global ceramide levels, as well as in reducing dihydrosphingosine levels. "